Mater Group was formed in 2016 by aligning Mater Health, Mater Education, Mater Research and Mater Foundation under a single, unified banner. Mater provides care for some 500,000 patients each year. Mater was established in 1906 by the Sisters of Mercy.

During the past decade, Mater Health Services conducted 27 clinical trials. In the 10-year time frame, 27 clinical trials started and 8 clinical trials were completed, i.e. on average, 29.6% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 5 clinical trials were completed. i.e. 55.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mater Health Services" #1 sponsor was "Pfizer" with 6 trials, followed by "Queensland Centre for Gynaecological Cancer" with 4 trials sponsored, "Galapagos NV" with 3 trials sponsored, "Australian and New Zealand Intensive Care Research Centre" with 2 trials sponsored and "Gilead Sciences" with 2 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mater Health Services" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "The University of Queensland" with 3 trials as a collaborator, "ANZICS Clinical Trials Group" with 2 trials as a collaborator, "Cancer Australia" with 2 trials as a collaborator and "Medical Research Institute of New Zealand" with 2 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "Mater Health Services" are "Crohn's Disease" (5 trials), "Ulcerative Colitis" (5 trials), "Cervical Cancer" (3 trials), "Fallopian Tube Cancer" (2 trials) and "Ovarian Cancer" (2 trials). Many other conditions were trialed in "Mater Health Services" in a lesser frequency.

Most popular intervention types in "Mater Health Services" are "Drug" (23 trials), "Device" (3 trials), "Behavioral" (2 trials), "Biological" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Filgotinib" (4 trials), "0 mg Induction ONLY" (1 trials), "150 mg Induction/Chronic" (1 trials) and "225mg SHP647 (PF-00547659)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Mater Health Services" are 25 trials for "All" genders and 9 trials for "Female" genders.

Currently, there are NaN active trials in "Mater Health Services". undefined are not yet recruiting, 3 are recruiting, 6 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 20 completed trials in Mater Health Services, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Mater Health Services, 2 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".

Mater Health Services has several departments that took part in Clinical trials: "Mater Cancer Care Centre" - 12 trials, "Radiation Oncology - Mater Centre" - 8 trials, "Mater Children's Hospital" - 5 trials, "Mater Private Cardiology" - 2 trials